DK1509525T5 - Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor - Google Patents

Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor

Info

Publication number
DK1509525T5
DK1509525T5 DK03734281T DK03734281T DK1509525T5 DK 1509525 T5 DK1509525 T5 DK 1509525T5 DK 03734281 T DK03734281 T DK 03734281T DK 03734281 T DK03734281 T DK 03734281T DK 1509525 T5 DK1509525 T5 DK 1509525T5
Authority
DK
Denmark
Prior art keywords
precursors
inhibitors
xanthine phosphodiesterase
preparing xanthine
preparing
Prior art date
Application number
DK03734281T
Other languages
Danish (da)
English (en)
Other versions
DK1509525T3 (da
Inventor
Cecilia A Orr
Fucheng Zhang
Vilas H Dahanukar
Hoa N Nguyen
Ilia A Zavialov
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1509525T3 publication Critical patent/DK1509525T3/da
Publication of DK1509525T5 publication Critical patent/DK1509525T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK03734281T 2002-05-31 2003-05-30 Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor DK1509525T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38447802P 2002-05-31 2002-05-31
PCT/US2003/017042 WO2003101992A1 (en) 2002-05-31 2003-05-30 Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof

Publications (2)

Publication Number Publication Date
DK1509525T3 DK1509525T3 (da) 2006-12-11
DK1509525T5 true DK1509525T5 (da) 2007-07-30

Family

ID=29712039

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03734281T DK1509525T5 (da) 2002-05-31 2003-05-30 Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor

Country Status (17)

Country Link
US (2) US7074923B2 (de)
EP (1) EP1509525B9 (de)
JP (1) JP2005529934A (de)
CN (2) CN101538224A (de)
AR (1) AR040232A1 (de)
AT (1) ATE336494T1 (de)
AU (1) AU2003238822A1 (de)
CA (1) CA2483923A1 (de)
CY (1) CY1105774T1 (de)
DE (1) DE60307628T2 (de)
DK (1) DK1509525T5 (de)
ES (1) ES2270047T3 (de)
HK (1) HK1068139A1 (de)
MX (1) MXPA04011862A (de)
PT (1) PT1509525E (de)
WO (1) WO2003101992A1 (de)
ZA (1) ZA200408719B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
EP1757606B1 (de) * 2001-02-24 2009-05-06 Boehringer Ingelheim Pharma GmbH & Co. KG Xanthinderivate Verwendung als Arzneimittel sowie deren Verfahren zur deren Herstellung
US7192962B2 (en) * 2002-05-31 2007-03-20 Schering Corporation Xanthine phosphodiesterase V inhibitor polymorphs
EP1521584A1 (de) * 2002-06-17 2005-04-13 Glaxo Group Limited Purin-derivate als leber x-rezeptor-agonisten
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
EP1648895B1 (de) * 2003-07-31 2007-05-30 Schering Corporation Metabolit eines xanthinphosphodiesterase-5-inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen
TW200526664A (en) * 2003-11-21 2005-08-16 Schering Corp Phosphodiesterase V inhibitor formulation
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) * 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN101437823B (zh) 2006-05-04 2014-12-10 勃林格殷格翰国际有限公司 多晶型
EP1852108A1 (de) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
WO2008017670A1 (en) 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
KR101610005B1 (ko) * 2007-08-17 2016-04-08 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ 관련 질환의 치료에 사용하기 위한 푸린 유도체
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CN103816158A (zh) * 2008-08-15 2014-05-28 勃林格殷格翰国际有限公司 用于治疗fab-相关疾病的嘌呤衍生物
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP2731947B1 (de) 2011-07-15 2019-01-16 Boehringer Ingelheim International GmbH Substituiertes dimeres chinazolin derivat, dessen herstellung und verwendung in pharmazeutischen zusammensetzungen zur behandlung von typ i und typ ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (de) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH Xanthinderivat als dpp-4-hemmer zur verwendung bei der behandlung von durch podozyten vermittelten erkrankungen und/oder des nephrotischen syndroms
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (de) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medizinische verwendung eines dpp-4-inhibitors
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) * 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
JPH0372480A (ja) * 1989-08-10 1991-03-27 Hokuriku Seiyaku Co Ltd キサンチン誘導体及びそれらを有効成分とする気管支拡張剤
CA2030112A1 (en) 1989-11-24 1991-05-25 Yasuo Ito Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same
ZA914727B (en) * 1990-06-21 1992-03-25 Schering Corp Polycyclic guanine derivatives
JPH04128285A (ja) * 1990-06-27 1992-04-28 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH04279586A (ja) * 1991-03-05 1992-10-05 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH051065A (ja) * 1991-06-20 1993-01-08 Hokuriku Seiyaku Co Ltd キサンチン誘導体
DE59208572D1 (de) * 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
DE4411660A1 (de) * 1994-04-05 1995-10-12 Hoechst Ag Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
ATE226583T1 (de) * 1996-06-07 2002-11-15 Hoechst Ag Verwendung von theophyllinderivaten zur behandlung und propylaxe von schockzuständen, neue xanthinverbindungen und verfahren zu deren herstellung
AU6895801A (en) * 2000-07-04 2002-01-14 Novo Nordisk As Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
EP1757606B1 (de) * 2001-02-24 2009-05-06 Boehringer Ingelheim Pharma GmbH & Co. KG Xanthinderivate Verwendung als Arzneimittel sowie deren Verfahren zur deren Herstellung
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
AR036674A1 (es) 2001-08-28 2004-09-29 Schering Corp Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicos
EP1463727A2 (de) * 2001-09-19 2004-10-06 Novo Nordisk A/S Heterocyclische verbindungen, bei denen es sich um inhibitoren des enzyms dpp-iv handelt
EP1442042A1 (de) 2001-11-09 2004-08-04 Schering Corporation Polyzyklisches guaninderivat phosphodiesterase-v-inhibitoren
JP2005513165A (ja) * 2002-01-11 2005-05-12 ノボ　ノルディスク　アクティーゼルスカブ 糖尿病、高血圧、慢性心不全および体液貯留状態の治療のための方法および組成物
JP2004043429A (ja) * 2002-02-25 2004-02-12 Eisai Co Ltd 新規キサンチン誘導体およびｄｐｐｉｖ阻害剤
US7192962B2 (en) * 2002-05-31 2007-03-20 Schering Corporation Xanthine phosphodiesterase V inhibitor polymorphs
EP1521584A1 (de) * 2002-06-17 2005-04-13 Glaxo Group Limited Purin-derivate als leber x-rezeptor-agonisten
BRPI0313648B8 (pt) * 2002-08-21 2021-05-25 Boehringer Ingelheim Pharma 8-[3-amino-piperidin-1-il]-xantinas, seus sais fisiologicamente compatíveis, seus usos e seus processos de preparação, bem como medicamentos que as contêm e seus processos de preparação
AU2003269850A1 (en) * 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
WO2004048379A1 (ja) * 2002-11-01 2004-06-10 Sumitomo Pharmaceuticals Co., Ltd. キサンチン化合物
WO2005009343A2 (en) * 2003-06-06 2005-02-03 Endacea, Inc. A1 adenosine receptor antogonists
EP1648895B1 (de) * 2003-07-31 2007-05-30 Schering Corporation Metabolit eines xanthinphosphodiesterase-5-inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
ATE336494T1 (de) 2006-09-15
WO2003101992A1 (en) 2003-12-11
CA2483923A1 (en) 2003-12-11
AU2003238822A1 (en) 2003-12-19
EP1509525B1 (de) 2006-08-16
HK1068139A1 (en) 2005-04-22
CN101538224A (zh) 2009-09-23
US20030232987A1 (en) 2003-12-18
DK1509525T3 (da) 2006-12-11
CY1105774T1 (el) 2011-02-02
MXPA04011862A (es) 2005-03-31
AR040232A1 (es) 2005-03-23
US7786301B2 (en) 2010-08-31
DE60307628D1 (de) 2006-09-28
JP2005529934A (ja) 2005-10-06
EP1509525A1 (de) 2005-03-02
PT1509525E (pt) 2006-12-29
ES2270047T3 (es) 2007-04-01
CN100497336C (zh) 2009-06-10
US7074923B2 (en) 2006-07-11
US20060205943A1 (en) 2006-09-14
ZA200408719B (en) 2005-11-15
EP1509525B9 (de) 2007-10-31
DE60307628T2 (de) 2007-08-09
CN1668618A (zh) 2005-09-14

Similar Documents

Publication Publication Date Title
DK1509525T5 (da) Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor
DK1644384T3 (da) Fremgangsmåde og mellemprodukter til syntese af entecavir
IS7606A (is) Aðferð til þess að búa til pyrimídín og pyrimídínafleiður sem eru tálmar prótín kínasa
IS7700A (is) Ný spíróþétt kínasólínón og notkun þeirra sem fosfórdíesterasa hindrar
IS7599A (is) Heterósýklískir kínasatálmar
DK1398327T3 (da) Fremgangsmåde til fremstililng af hydroxyalkylstivelsesderivater
DE60304911D1 (de) Xanthin-Derivate als DPP-IV-Inhibitoren
ATE505471T1 (de) Azaindol-kinaseinhibitoren
DK1606283T3 (da) P38-inhibitorer og fremgangsmåder til anvendelse deraf
IS8037A (is) P38-hindrar og aðferðir til notkunar þeirra
AP2007004004A0 (en) Pyrrolidyl derivatives of heteroaromatic compoundsas phosphodiesterase inhibitors
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
NO20042147L (no) Heterocykliske forbindelser og fremgangsmater for anvendelse derav
HK1118274A1 (en) Quinoline derivatives as phosphodiesterase inhibitors
EP1496910A4 (de) Kinase-hemmer
ATE288436T1 (de) Pyrimidinderivate zum inhibieren der zellproliferation
DK1656370T3 (da) Heterocykliske biarylforbindelser og fremgangsmåder til fremstilling og anvendelse af samme
HK1068140A1 (en) Xanthine phosphodiesterase v inhibitor polymorphs
EP1558609A4 (de) Kinase-hemmer
DK1590360T3 (da) Fremgangsmåde til fremstilling af inhibitorer af nukleosidphosphorylaser og nukleosidaser
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
EP1570847A4 (de) Phosphodiesterase 10a-hemmer
DK1342743T3 (da) Fremgangsmåde til fremstillinmg af et pulver med höjt tanninindhold og dets anvendelse
EP1569907A4 (de) Nicotinamid-basierte kinasehemmer
DK1663997T3 (da) 1h-azolyl-methyl-amider, fremgangsmåde til fremstilling deraf og anvendelse deraf som nitrifikationsinhibitorer